More biologic-based therapies translates into more cold chain activity. As yet, new cellular and genetic therapies are a minute part of the overall market.
Mark Lipowicz, Contributing Editor
Advertisement
Articles by Mark Lipowicz, Contributing Editor
Advertisement
Latest Updated Articles
- Biopharma cold-chain market forecast
Published: September 4th 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
One Connection, Endless Impact: Improving Patient Medication Access
2
Optimizing Your CGT Commercial Distribution Strategy: Four Priorities for a Successful Launch
3
Why Continuous Vendor Oversight Is Key to Healthcare Data Security
4
